In this study, a radiogenomic signature from the tumor and tumor environment characterizing the response-associated HER2-E subtype was identified, applied to estimate response to anti-HER2 therapy, and then correlated with pathologic immune response on corresponding biopsy images. Here, ERBB2 is linked to neoplasm.